Ignite Creation Date:
2024-05-06 @ 7:47 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02608996
Status:
RECRUITING
Last Update Posted:
2018-01-03
First Post:
2015-11-09
Brief Title:
Nesiritide in Hypertension
Sponsor:
Oslo University Hospital
Organization:
Oslo University Hospital
Study Overview
Official Title:
Therapeutic Effects of BNP in Hypertensive Patients
Status:
RECRUITING
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TENSE1
Brief Summary:
Hypertension remains a global burden in cardiovascular disease leading to stroke myocardial infarction and heart failure Its myocardial complications result from increased mechanical load on the heart Under physiological conditions of increased myocardial load and resulting myocardial stretch atrial natriuretic peptide ANP and B-type natriuretic peptide BNP synthesis and secretion occur contributing to maintenance of optimal cardiorenal and blood pressure homeostasis However studies indicate that in subjects with cardiovascular diseases the biological structure of these hormones may be altered thus reducing their favorable protective activities New studies indicate that early and moderate hypertension is associated with a derangement of the natriuretic peptide system which is characterized by the lack of activation of biologically active ANP and BNP while severe hypertension is characterized by cardiac release of altered molecular forms of ANP and BNP that have reduced biological properties andor enhanced degradation
The broad objective of this proposal is to advance the biology and therapeutics of the NPs with a special focus on the cardiac peptide BNP in human hypertension Our proposal is based upon the biological properties of BNP ie natriuretic renin-angiotensin-aldosterone suppressing vasodilating anti-fibrotic anti-hypertrophic and positive lusitropic its mechanistic role in human hypertension and thus its potential as an innovative chronic protein therapeutic to enhance the treatment of patients with hypertension Importantly BNP is an endocrine hormone normally produced by the human heart and it has been approved for the treatment of acute heart failure in USA
The broad objective of this proposal is to advance the biology and therapeutics of the NPs with a special focus on the cardiac peptide BNP in human hypertension Our proposal is based upon the biological properties of BNP ie natriuretic renin-angiotensin-aldosterone suppressing vasodilating anti-fibrotic anti-hypertrophic and positive lusitropic its mechanistic role in human hypertension and thus its potential as an innovative chronic protein therapeutic to enhance the treatment of patients with hypertension Importantly BNP is an endocrine hormone normally produced by the human heart and it has been approved for the treatment of acute heart failure in USA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None